Russia & EAEU (Eurasian Economic Union)

AI Citation Summary

• Country: Russia & EAEU (Eurasian Economic Union)
• Product line: Medical devices
• Regulator / source: > In light of the geopolitical situation since 2022, Western countries have imposed extensive export controls and financial sanctions on Russia. Before deciding to register and sell medical devices in Russia/EAEU, you must consult export compliance legal counsel (particularly for devices incorporating controlled technology). This document is provided for regulatory process reference only and does not constitute commercial or legal advice. Violations of applicable sanctions regimes can result in severe criminal and civil liability.
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Roszdravnadzor may require confirmatory clinical investigations at Russian medical institutions; timelines are 6–18 months
• Key fees: Market characteristics: Russia was formerly one of the world's top ten medical device markets (annual market size ~USD 4–5 billion). Since 2022, structural changes have occurred due to sanctions, ruble depreciation, and the withdrawal of Western brands. Import substitution policies (Импортозамещение) are accelerating. Kazakhstan has become a "transit registration hub" for some Western companies seeking to avoid sanctions, though the gray-area compliance risk is substantial.
• Local requirement: Russia & EAEU medical-device entry should be separated into Roszdravnadzor and EAEU medical-device framework regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

⚠️ SANCTIONS COMPLIANCE WARNING — READ BEFORE PROCEEDING

In light of the geopolitical situation since 2022, Western countries have imposed extensive export controls and financial sanctions on Russia. Before deciding to register and sell medical devices in Russia/EAEU, you must consult export compliance legal counsel (particularly for devices incorporating controlled technology). This document is provided for regulatory process reference only and does not constitute commercial or legal advice. Violations of applicable sanctions regimes can result in severe criminal and civil liability.

Market Overview

• Population: The five EAEU member states total approximately 185 million (Russia ~145 million, Kazakhstan ~19 million, Belarus ~9.4 million, Armenia ~3 million, Kyrgyzstan ~6.8 million)
• Healthcare system: Russia's system is centered on mandatory health insurance (OMS, Обязательное медицинское страхование); public hospitals are the primary procurement channel. Kazakhstan has been actively modernizing its healthcare infrastructure in recent years; Belarus operates a Soviet-style national healthcare system.
• Market characteristics: Russia was formerly one of the world's top ten medical device markets (annual market size ~USD 4–5 billion). Since 2022, structural changes have occurred due to sanctions, ruble depreciation, and the withdrawal of Western brands. Import substitution policies (Импортозамещение) are accelerating. Kazakhstan has become a "transit registration hub" for some Western companies seeking to avoid sanctions, though the gray-area compliance risk is substantial.
• Regulatory maturity: Medium. The EAEU unified registration system (TR EAEU 017/2011) is established, but enforcement varies across member states. Russia's Roszdravnadzor enforcement is comparatively rigorous. Since 2022, foreign companies operating in Russia face significant compliance and commercial risks.

Market-Entry Logic

Russia & EAEU medical-device entry should be separated into Roszdravnadzor and EAEU medical-device framework regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.

Entry layer	Key question	Practical view
Regulatory route	Which product category, risk class, application type, reliance route, or special pathway applies?	Confirm the pathway before translating the dossier; route choice drives evidence, timing, fees, inspections, labelling, and change-control obligations
Local execution	Who holds the registration, imports, answers regulator questions, manages safety reporting, and controls renewals or variations?	Contract structure matters because local agents, sponsors, distributors, or licence holders can control practical market access even when the foreign manufacturer owns the product
Evidence and economics	What clinical, quality, performance, HTA, pricing, and budget-impact evidence is needed?	Registration evidence and payer evidence should be planned together; otherwise approval may be achieved without reimbursement, tender access, or hospital adoption
Channel access	Which payer, hospital, distributor, retail, tender, or private-care channel will create volume?	Start with the channel that matches product value and service burden; premium products often need reference sites before broad tender or retail expansion

Main Players and Channel Map

Type	Representative players	Market meaning
Regulator / review	Roszdravnadzor and EAEU medical-device framework	Determines approval route, technical evidence, inspections, labelling, post-market duties, renewals, and variations
Payment / procurement	OMS public insurance, state procurement, regional tenders and private hospital channels	Determines reimbursement, tender economics, price ceilings, purchasing lists, and patient affordability
Companies / channels	Shvabe, Rostec-linked suppliers, local importers, regional distributors, public hospitals and EAEU authorised representatives	Shows the competitive set, partner universe, distribution power, hospital access points, and local execution benchmarks
End users / buyers	Public hospitals, private hospital groups, specialist centers, laboratories, pharmacies, insurers, and regional distributors	Determine adoption, tender volume, reference cases, service expectations, and receivables risk

Development Trends

1. Approval and access are increasingly separate: Technical approval does not guarantee reimbursement, procurement listing, physician adoption, or patient affordability.
2. Local execution quality is a major differentiator: Strong local regulatory, medical, market-access, distribution, and service teams reduce deficiency, launch, and lifecycle risk.
3. Evidence expectations are rising: Payers and hospitals increasingly ask for comparative clinical value, real-world evidence, budget impact, and operational service data.
4. Pricing pressure is structural: sanctions and export-control screening, import substitution, EAEU dossier conversion, payment logistics, local representative risk and public procurement localisation are reshaping launch sequencing and product economics.
5. Partner control should be managed early: Contracts should protect dossier access, registration ownership, renewal obligations, safety reporting, inventory, and transition rights.

Regulatory Authorities

• Competent Authority (Russia): Roszdravnadzor (Federal Service for Surveillance in Healthcare, Федеральная служба по надзору в сфере здравоохранения), under the Russian Ministry of Health
• EAEU level: The Eurasian Economic Commission (EEC, Евразийская экономическая комиссия) issues unified technical regulations
• Official portals:
  • Roszdravnadzor: https://www.roszdravnadzor.gov.ru
  • FGIS Roszdravnadzor (Federal State Information System): https://fgisrz.roszdravnadzor.gov.ru
  • EAEU EEC: https://www.eurasiancommission.org
• Key regulations:
  • TR EAEU 017/2011 (Technical Regulation of the Customs Union on the Safety of Medical Devices, Технический регламент Таможенного союза о безопасности медицинских изделий) — the unified EAEU technical regulation applicable across all five member states
  • Russian Federal Law No. 323-FZ "On the Fundamental Principles of the Protection of the Health of Citizens of the Russian Federation"
  • Russian Government Decree No. 1416 (state registration procedure for medical devices)
  • Supplementary national regulations in each member state (Kazakhstan, Belarus, etc. have their own implementing rules)

Device Classification

Local Classification	Risk Level	EU/FDA Equivalent	Notes
Класс 1 (Class 1)	Low risk	EU Class I / FDA Class I	General devices, lowest risk
Класс 2 (Class 2)	Medium risk	EU Class IIa / FDA Class II	Medium risk; conformity assessment body involvement required
Класс 2а (Class 2а)	Medium-high risk	EU Class IIb / FDA Class II	Some literature treats Classes 2 and 2а together
Класс 2б (Class 2б)	Higher risk	EU Class IIb / FDA Class II–III	More rigorous review
Класс 3 (Class 3)	High risk	EU Class III / FDA Class III	Implants, life-sustaining devices, etc.; strictest controls

EAEU classification rules are set out in Annex 1 of TR EAEU 017/2011. They reference but are not fully equivalent to EU MDR classification rules.

Registration Pathway

Pathway for Foreign Manufacturers (EAEU Unified Registration)

1. Appoint an EAEU Authorized Representative (АП, Уполномоченный Представитель)

   • The Authorized Representative must be a legal entity registered in one of the five EAEU member states
   • The representative bears legal responsibility within the Roszdravnadzor/EAEU system
   • Russia or Kazakhstan is recommended (larger markets; more established regulatory bodies)

2. Prepare the Technical Documentation

   • Technical documentation (Регистрационное досье) must be prepared per TR EAEU 017/2011 requirements
   • All documents must have certified Russian-language translations
   • The dossier must include: product description, design documentation, risk analysis, biocompatibility report, clinical data, etc.

3. Conformity Assessment Body (Орган по оценке соответствия) evaluation (Class 2 and above)

   • Engage an EAEU-accredited conformity assessment body to conduct the conformity evaluation
   • The registry of accredited bodies is searchable in the EAEU Unified Information System (ЕАИС)
   • The conformity assessment body issues a Certificate of Conformity (Сертификат соответствия)

4. Clinical investigation / clinical evaluation (where required)

   • Class 2б and Class 3 devices typically require clinical investigation data conducted in Russia or within the EAEU
   • Roszdravnadzor may require confirmatory clinical investigations at Russian medical institutions; timelines are 6–18 months
   • Exemption applications using international clinical data are possible but approval rates are inconsistent

5. Submit the state registration application to Roszdravnadzor

   • Submit electronically through the FGIS Roszdravnadzor system
   • Submit paper originals to Roszdravnadzor's Moscow office
   • Pay the state registration fee (госпошлина)

6. Review and site inspection (mandatory for Class 3)

   • Roszdravnadzor reviews the technical documentation and may request supplementary materials (Запрос дополнительных материалов)
   • Class 3 devices require a manufacturing site inspection (Инспекция производства) by Roszdravnadzor experts
   • Foreign manufacturers must facilitate the inspection; remote video inspections are sometimes accepted

7. Obtain the State Registration Certificate (Регистрационное удостоверение, РУ)

   • Upon successful registration, Roszdravnadzor issues the РУ
   • EAEU-wide coverage: A registration certificate obtained in Russia is automatically valid in Belarus, Kazakhstan, Armenia, and Kyrgyzstan (and vice versa — registration in any one member state covers the entire EAEU market)

Key Prerequisites

• Valid Authorized Representative agreement (bilingual: Russian + original language)
• Complete Russian-language technical dossier (certified translations)
• Conformity assessment body certificate (Class 2 and above)
• ISO 13485 certificate (current), or equivalent QMS documentation
• Certificate of Free Sale (CFS) from the manufacturer's home country: notarized + Russian consulate legalization (или апостиль)

Registration Dossier Requirements

• ISO 13485 certificate (current; equivalent QMS documentation accepted if unavailable; certified Russian translation required)
• Certificate of Free Sale (CFS) (Сертификат свободной продажи; notarized + legalized)
• Device description and intended purpose (Russian version)
• Full technical dossier (per the annex format of TR EAEU 017/2011; includes design documentation, test reports, risk analysis)
• Biocompatibility report (ISO 10993 series; Russian translation)
• Clinical evidence (clinical evaluation report or local clinical investigation report; Class 2б/3 typically requires local data)
• IFU/labeling (Russian version; must comply with Russian labeling requirements)
• Conformity assessment body certificate (Class 2 and above)
• Letter of Authorization for Authorized Representative (notarized + consulate/Apostille legalization)
• Proof of legal entity for manufacturer (notarized + legalized)
• State registration application form (in Russian; per Roszdravnadzor format)
• Product samples (Roszdravnadzor may request physical samples for testing)

Common pitfall: Russian technical documentation requirements are extremely detailed. Translation errors or format non-compliance cause review delays. Engage a Russian regulatory affairs firm with proven Roszdravnadzor filing experience to prepare the dossier.

Registration Timelines

Stage	Official Timeframe	Practical Reference
Technical documentation preparation (including Russian translation)	—	3–6 months
Conformity assessment body evaluation (Class 2)	60 business days	3–6 months
Conformity assessment body evaluation (Class 3)	90 business days	6–12 months
Roszdravnadzor administrative review (Class 1/2)	60–90 business days	6–12 months
Roszdravnadzor review (Class 2б/3, including clinical)	90–160 business days	12–24 months
Site inspection scheduling (Class 3)	—	Additional 3–6 months
Total timeline reference (Class 2б/3)	—	18–36 months

Practical note: The Roszdravnadzor review clock stops when supplementary information is requested, and multiple rounds may occur. Since 2022, foreign companies have encountered payment difficulties due to sanctions (e.g., inability to transfer funds into Russia); payment channels must be planned in advance.

Registration Costs

Item	Estimated Cost (USD)
Roszdravnadzor state registration fee (госпошлина, Class 1/2)	~200–600
Roszdravnadzor state registration fee (Class 2б/3)	~600–1,500
Conformity assessment body evaluation (Class 2)	3,000–8,000
Conformity assessment body evaluation (Class 3)	8,000–20,000
Russian-language technical dossier translation (full set)	5,000–20,000 (depending on volume)
Local clinical investigation (if required; Class 2б/3)	15,000–80,000+
Authorized Representative annual fee	5,000–20,000/year
Notarization + consulate legalization	1,000–3,000
Regulatory affairs consultant fee	5,000–15,000
Total budget reference (Class 2б, single device, no local clinical)	~30,000–70,000
Total budget reference (Class 3, including local clinical)	~80,000–200,000+

Note: After 2022, significant ruble depreciation means that Russia-based fees denominated in rubles may result in lower USD equivalents. However, the practical cost of banking transactions has increased due to sanctions restrictions.

Local Agent / Marketing Authorization Holder Requirements

• Local agent mandatory: Yes. Foreign manufacturers cannot directly hold Russian/EAEU registration certificates; an EAEU-based legal entity must serve as Authorized Representative (АП).
• Representative qualifications:
  • Must be a legal entity registered in an EAEU member state
  • Must be registered as an Authorized Representative with Roszdravnadzor (a dedicated registration procedure applies)
  • Must possess professional qualifications in medical devices and be responsible for post-market regulatory reporting
  • Bears joint compliance liability with the manufacturer
• Marketing authorization holder rules:
  • The registration certificate (РУ) is issued in the Authorized Representative's name (unlike Turkey, in Russia the РУ holder is typically the Authorized Representative, not the manufacturer)
  • Changing the Authorized Representative requires a registration certificate variation application; product supply must not be interrupted during the transition
  • Important: If the Authorized Representative is restricted due to sanctions or compliance issues, the registration certificate may enter a legal gray area

Import Requirements

• Import permit: Importation is based on a valid registration certificate (РУ); the customs code must match the registration certificate
• Customs requirements:
  • Must provide: Russian-language product labeling, conformity documentation, copy of the registration certificate
  • HS code must be accurate; some medical devices are eligible for zero or preferential tariff rates (verify the specific tariff heading)
  • Importers must be registered with Russian customs and retain import records for post-market surveillance purposes
• Labeling language: Russian is mandatory; must include: product name (in Russian), manufacturer information, Authorized Representative information, manufacturing date/lot number, expiry date, safety warnings, and storage conditions

Post-Market Surveillance

• Adverse event reporting (НПР, Нежелательные Побочные Реакции):
  • Serious adverse events must be reported to Roszdravnadzor within 10 business days
  • Immediately life-threatening events must be reported within 72 hours
  • Reports submitted through the FGIS Roszdravnadzor system
• Recall rules: The manufacturer or Authorized Representative must execute recalls per Roszdravnadzor directives, issue public recall notices, and report progress to the regulatory authority
• Periodic safety reports (ПОД, Периодический Отчет): High-risk products must submit periodic safety update reports; specific format and frequency are determined by Roszdravnadzor
• Post-market surveillance: Roszdravnadzor conducts random sampling and testing of marketed products; quality issues may result in suspension of the РУ

Renewal Requirements

• Registration certificate validity:
  • New registrations: Typically issued with indefinite validity (бессрочное), but continuous compliance must be maintained
  • Some older РУs have 5-year terms; renewal is required upon expiry
• Renewal timing: РУs with a fixed term must be renewed 6 months before expiry
• Key maintenance obligations:
  • Changes in manufacturer information, contact details, or Authorized Representative must be promptly reported to Roszdravnadzor
  • Significant design changes require a new registration or a variation application
  • ISO 13485 certificate renewals must be promptly updated with Roszdravnadzor

Special Regulatory Requirements

• UDI / product traceability:
  • Russia is advancing a medical device traceability system (an extension of the MDLP-type system); currently under development
  • High-risk products must have serial/lot number information registered in FGIS Roszdravnadzor
  • The EAEU is discussing a unified UDI framework; not yet fully implemented
• Local testing:
  • Roszdravnadzor may require local testing of foreign-manufactured products at Russian-accredited laboratories in specific cases
  • Radiation-emitting devices must be recognized by the Russian national standards body (Росстандарт)
• Import substitution policy (Импортозамещение):
  • The Russian government is actively promoting medical device localization; restrictions apply to foreign products in government procurement
  • Since 2022, certain foreign products have been barred from federal government procurement to support domestic brands
• Sanctions compliance:
  • US EAR (Export Administration Regulations), EU dual-use export controls, UK sanctions, and others may restrict the export of specific devices to Russia
  • Devices incorporating controlled chips, software, or technology must be assessed individually for export control applicability

Market Access Channels

• Public hospital procurement (госзакупки): The largest channel; conducted through the national procurement platform (zakupki.gov.ru, Единая Информационная Система в Сфере Закупок) via public tender. Inclusion in the federal/regional medical device procurement list (перечень) is key to securing public hospital orders; a valid РУ and compliance with import substitution policies are required.
• Private hospitals/clinics: Account for approximately 20–25% of the market; concentrated in Moscow, St. Petersburg, and other major cities; procurement decisions are relatively flexible, but since 2022 payment routes for foreign products have been impeded
• E-commerce/distribution: B2B distribution dominates; consumer medical devices (blood pressure monitors, blood glucose meters, etc.) are sold through pharmacies (аптека) and e-commerce platforms (Wildberries, Ozon, etc.)
• Kazakhstan / other EAEU countries: As an "alternative entry point" — some European companies complete EAEU registration through Kazakhstan and sell to Kazakhstan and Central Asian markets. Note: EAEU registration covers Russia, but actual exports to Russia still require compliance with each country's export control regulations.

Market Entry Strategy

• Recommended approach (2024–2026):

  • Russian market: Given sanctions and geopolitical risks, Western and European companies are strongly advised to consult legal counsel to assess export compliance before deciding whether to proceed with registration. Existing РУs can be maintained at relatively low cost, but new investment requires careful evaluation.
  • Kazakhstan: As the preferred EAEU entry point; Astana/Almaty market is growing healthily with manageable political risk. Engage a local distributor to complete EAEU registration and focus Kazakhstan as the primary sales market.
  • Armenia: A low-risk option for a small-scale EAEU registration pilot; the regulatory body is small and approvals are relatively flexible.

• Key risks:

  1. Sanctions compliance risk: Selling medical devices incorporating controlled technology to Russia may violate US EAR, EU export controls, or domestic laws; the legal consequences are severe
  2. Payment route disruption: SWIFT sanctions make fund transfers to Russia extremely difficult; routing through third-country banks carries high compliance risk
  3. Authorized Representative reliability: Russian Authorized Representatives may face secondary sanctions impacts; their compliance status must be continuously assessed
  4. Registration certificate ownership risk: Russian РУs are held in the Authorized Representative's name; if the relationship breaks down, the manufacturer has little direct control over the registration certificate
  5. Market contraction: Large numbers of Western companies have exited the Russian market; market structure is being restructured, with domestic and Chinese brands filling the gap

• Practical tips:

  • If maintaining Russian registrations, work with a law firm specializing in sanctions compliance and review export compliance status quarterly
  • The legal gray-zone nature of using Kazakhstan as a "transit registration hub to circumvent Russian sanctions" is being clamped down upon; do not use Kazakhstan registration as the business rationale for sales ultimately destined for Russia in violation of sanctions
  • Once EAEU registration is completed, sales through legitimate channels to Kazakhstan, Armenia, and Kyrgyzstan are cleaner from a compliance perspective

Leveraging Existing CE / FDA / NMPA Approvals

Quick Reference

Certificate	Acceleration Effect	Primary Mechanism
EU CE (MDR/IVDR)	⭐⭐ (document reference; exercise caution given current geopolitical environment)	The EAEU system is entirely independent; CE cannot be used directly for registration. However, CE technical documentation is a good foundation for the EAEU registration dossier.
US FDA (510(k)/PMA)	⭐⭐ (document reference; additional complexity under sanctions environment)	Similar to CE; under the sanctions context, FDA approval may attract additional scrutiny from reviewers
China NMPA	⭐⭐ (symbolic value; no formal fast-track)	Deeper EAEU–China ties in the current geopolitical context; NMPA certificate carries some positive impression

EU CE (MDR/MDD/IVDR)

• Recognition mechanism: The EAEU (Eurasian Economic Union) has established a completely independent medical device registration system (TR EAEU 017/2011) that is not mutually recognized with the EU MDR/CE framework. CE marking carries no legal weight in an EAEU registration application and cannot substitute for any step required by TR EAEU. However, since TR EAEU technical regulations were partly designed with reference to EU technical regulation frameworks, the technical documentation accumulated during CE certification (ISO 13485 QMS files, ISO 14971 risk management report, biocompatibility reports, design V&V records, clinical data summaries) can serve as good source material for the EAEU registration dossier (Регистрационное досье) after structural adaptation. This can reduce documentation preparation effort by approximately 20–35% compared to starting from scratch, primarily saving effort on risk analysis, technical specifications, and test report organization.
• Practical effect: The reuse value of CE technical documentation is substantive but limited, because the EAEU registration dossier format (in Russian, with chapter structure per TR EAEU annexes) differs significantly from the EU MDR format and requires professional adaptation and certified Russian translation. Since 2022, geopolitical factors add additional complexity: CE certificates issued by EU Notified Bodies may trigger heightened scrutiny related to "Western associations" in the eyes of some Russian reviewers. Under the current sanctions environment, handle this carefully. Roszdravnadzor has tightened its review procedures for EU and US manufacturers; registration timelines may be extended.
• Key considerations: In the current sanctions context, submitting technical documentation that includes EU NB certificates and EU test laboratory reports to Russian authorities may raise export control compliance questions regarding the technology origin of the device (particularly for products with dual-use technology). Confirm all technical origin information in the dossier with export compliance counsel before submission.

US FDA (510(k) / De Novo / PMA)

• Recognition mechanism: FDA approval carries no formal legal standing in the EAEU registration system and cannot substitute for any step in the TR EAEU registration process. As with CE, FDA-review-generated technical documentation (clinical data, risk management, design documentation) can serve as content reference for the EAEU dossier, but structural conversion costs are high and full Russian-language processing is required.
• Practical effect: Document reference value is equivalent to CE (⭐⭐). However, the current sanctions environment adds additional complexity: FDA-approved products may be identified by Russian authorities as "Western products subject to sanctions," which may result in heightened scrutiny or passive delays in national procurement reviews. From a commercial strategy perspective, submitting registration applications containing FDA approval information to Russia requires a comprehensive legal assessment of export compliance and sanctions risks.
• Key considerations: EAR (Export Administration Regulations), OFAC sanctions, and EU export controls impose specific restrictions on the transfer of controlled technology to Russia. The "humanitarian exemption" applicable to medical devices has defined conditions — do not assume all medical devices are automatically exempt. Conduct a product-by-product export compliance review (EAR ECCN classification assessment).

China NMPA

• Recognition mechanism: EAEU–China relations have deepened significantly since 2022. Russia has identified regulatory cooperation with China as a priority agenda item. However, as of this document's update, no formal medical device registration mutual recognition mechanism (MRA) has been established between the EAEU and China. NMPA certificates carry no legal weight in EAEU registration applications and cannot substitute for any TR EAEU step. In practice, some Chinese-manufactured products holding NMPA certificates occasionally receive an informal positive impression — a kind of "friendly market" signal — in non-formal Roszdravnadzor assessments, but this is not a systematic mechanism and is highly dependent on the specific reviewer and product category.
• Practical effect: Symbolic positive impression (⭐⭐); no formal fast-track. Chinese manufacturers entering the EAEU market on the basis of existing NMPA registration have primary advantages in: (1) ISO 13485 QMS documentation (if established to international standards) can be used directly as the basis for the EAEU registration dossier; (2) clinical data from China can supplement the EAEU registration's clinical evidence (Russian translation required); (3) in the current political climate, Chinese brands are gaining significantly more commercial opportunities in the Russian market (filling the gap left by Western brands exiting), and NMPA certificates carry brand endorsement value.
• Key considerations: Despite the closer Russia–China relationship, the EAEU registration process itself (Russian-language documents, conformity assessment body evaluation, Roszdravnadzor review, РУ issuance) must be fully executed; NMPA certificates cannot simplify any formal step. Chinese manufacturers should seek Authorized Representatives in Russia or Kazakhstan with extensive experience in the EAEU system to take full advantage of the current commercial opportunity window.

Practical Recommendations

1. Sanctions compliance first: Before initiating EAEU registration, conduct a complete export compliance assessment (EAR ECCN classification, OFAC sanctions screening, EU export control review), with a written opinion from qualified export compliance counsel. There are no shortcuts in this step; the consequences of non-compliance are extremely serious.
2. Kazakhstan-first strategy: For companies that still wish to enter the EAEU market without directly entering Russia, Kazakhstan (KZ) is the comparatively lower compliance-risk entry point. Once EAEU registration is completed, legitimate sales to Kazakhstan, Kyrgyzstan, and Armenia are possible — and these countries are not on the core sanctions lists.
3. Standardized CE/FDA to Russian-format conversion: If proceeding with EAEU registration, build a standardized conversion template from "EU technical documentation → EAEU format," systematically adapting the core chapters of CE/FDA technical files (risk management, biocompatibility, design V&V) into TR EAEU format with certified professional Russian translation services, creating a reusable registration dossier library.
4. Window of opportunity for Chinese manufacturers: The market vacuum created by the mass withdrawal of Western brands since 2022 presents a significant opportunity for Chinese manufacturers. Prioritize product lines already marketed in China that meet EAEU requirements, and monitor the policy window as EAEU–China regulatory cooperation deepens and potential MRA negotiations progress.
5. Registration certificate risk mitigation: Russian РУs are held in the Authorized Representative's name. Ensure the contract clearly specifies registration certificate ownership provisions and the transfer arrangement upon termination of the agency relationship, to prevent loss of control over the registration certificate if the Authorized Representative relationship breaks down.